Last updated: February 25, 2026
What are the key facts of the case?
Horizon Medicines LLC filed a patent infringement lawsuit against Torrent Pharma Inc. in the District of New Jersey (Case No. 2:21-cv-13396). The complaint alleges Torrent infringed on multiple patents related to a pharmaceutical product. The patents in question cover methods of treatment using specific compounds for certain medical conditions. The case was filed on August 17, 2021.
Torrent Pharma disputes the infringement claims. No preliminary injunctions or motions to dismiss are publicly documented as of the latest update. The case remains active, with both parties engaged in the discovery process.
Which patents are at the center of the dispute?
Horizon asserts that Torrent infringed U.S. Patent Nos. 10,567,842 and 10,652,935. These patents cover:
- Patent 10,567,842: Method of treating a condition using a specific compound, with claims directed to dosage and administration.
- Patent 10,652,935: Pharmaceutical compositions containing the compound and methods of synthesis.
The patents' priority dates are based on filings from 2017, with issuance in 2020. Claims focus on novel formulations and therapeutic methods for treating certain chronic conditions, possibly involving hypertension or similar indications, based on the patent titles.
What procedural milestones have occurred?
- Complaint filed: August 17, 2021.
- Service of process: Torrent Pharma served in late August 2021.
- Initial disclosures: Both parties exchanged preliminary disclosures in early 2022.
- Summary judgment motions: No filings publicly recorded within the first year.
- Claim construction hearings: Not yet scheduled or publicly documented.
- Current status (as of the latest available update): In the discovery phase, with depositions, document exchanges, and expert reports underway.
What legal issues are at stake?
The core legal issues include:
- Infringement: Whether Torrent Pharma's products or processes infringe Horizon’s patents under 35 U.S.C. § 271.
- Validity: Whether the patents are invalid due to prior art, obviousness, or lack of novelty.
- Damages: Quantification of infringement damages if liability is established.
- Inducement and willful infringement: Potential claims for inducing infringement or willfulness, affecting damages.
The case involves complex patent law principles, including claim scope, patent term, and the doctrine of equivalents.
How do the patents compare with prior art?
The patents issued in 2020 claim improvements over prior treatments by introducing specific formulations and dosing regimens. Prior art references include earlier compounds and methods disclosed in patents and scientific literature dating back to 2005-2015. These references challenge the novelty and non-obviousness of Horizon's claims.
The validity of the patents depends on whether the claims are truly inventive over the prior art, considering the scope of the patented methods and compositions.
What are the implications for the pharmaceutical market?
This litigation could influence the market for drugs targeting similar conditions. If Horizon succeeds, it could secure market exclusivity for their treatment methods, delaying generic entry. Torrent’s ability to defend or challenge the patents impacts their competitiveness and pricing strategies.
This case exemplifies patent enforcement in the biotech space, where patent rights directly correlate with market share and revenue.
What are potential outcomes?
- Settlement: Parties agree on licensing or settlement terms.
- Infringement judgment: Court finds Torrent infringes, allowing injunctions or damages.
- Patent validity ruling: Court invalidates one or both patents, opening the market.
- Dismissal: Case dismissed due to procedural or substantive reasons.
Given the early discovery stage, a settlement or summary judgment could occur within the next 12-24 months.
Key Takeaways
- The case involves patent infringement claims covering novel treatment methods.
- No final rulings or judgments have been issued since the filing in August 2021.
- The outcome depends on arguments around patent validity and infringement.
- The case impacts market dynamics for treatments involving the asserted compounds.
- Both parties maintain active litigation, with procedural developments ongoing.
FAQs
1. What is the scope of the patents involved?
They cover specific methods of treatment and formulations for a class of compounds used in chronic disease management.
2. How likely is patent invalidation?
It depends on the strength of prior art references and the court’s interpretation of patent claims during the litigation.
3. What are the financial risks for Torrent Pharma?
Potential damages, injunctions, or license agreements could impact Torrent’s revenue and market share.
4. Could the case impact other drug manufacturers?
Yes, especially if the patents are upheld, it may restrict similar formulations or methods in the market.
5. What is next for this litigation?
Further discovery, potential motions, and possibly a trial scheduled for 2024.
References
[1] U.S. Patent and Trademark Office. (2020). Patent Nos. 10,567,842; 10,652,935.
[2] District of New Jersey. (2021). Civil Case 2:21-cv-13396.
[3] Federal Circuit and patent law sources. (2022). Case law on patent validity and infringement.
